We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+0.53%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$153M
AUM Growth
-$143M
Cap. Flow
-$124M
Cap. Flow %
-80.74%
Top 10 Hldgs %
97.34%
Holding
16
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$109M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$7.85M
3
REPL icon
Replimune Group
REPL
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$53.9M 35.13%
3,050,187
-311,619
-9% -$7.41M
NUVB icon
2
Nuvation Bio
NUVB
$2.24B
$25M 16.32%
15,072,340
– –
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$22.5M 14.67%
597,723
– –
ALPN
4
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.7M 10.22%
2,029,580
– –
IMA
5
ImageneBio Inc
IMA
$63.1M
$7.76M 5.06%
187,427
– –
THRX
6
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.32M 4.12%
711,479
– –
KRON
7
DELISTED
Kronos Bio
KRON
$5.57M 3.64%
3,818,283
– –
PRTK
8
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.01M 3.27%
1,971,241
– –
SPRB
9
Spruce Biosciences
SPRB
$119M
$4.78M 3.11%
28,814
– –
SANA icon
10
Sana Biotechnology
SANA
$885M
$2.76M 1.8%
843,750
– –
IMUX icon
11
Immunic
IMUX
$182M
$2.66M 1.74%
178,816
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$671K 0.44%
251,270
– –
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$510K 0.33%
275,513
– –
SNTI icon
14
Senti Biosciences Holdings
SNTI
$12.6M
$231K 0.15%
19,579
– –
CINC
15
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-560,985
Closed -$7.85M
IMGO
16
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
– –
-3,018,737
Closed -$109M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2023 Portfolio in Review

As of Q1 2023, Omega Fund Management held 16 positions worth $153M, down 48% from $297M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Omega Fund Management withdrew a net $124M in Q1 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Imago BioSciences, Inc. Common stock, an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management's biggest Q1 2023 reduction was Replimune Group, cutting an estimated $7.41M.
  • Omega Fund Management fully exited Imago BioSciences, Inc. Common stock in Q1 2023, selling an estimated $109M.
  • Omega Fund Management's ten largest holdings make up 97% of its $153M portfolio in Q1 2023.
  • Omega Fund Management opened 0 new positions and closed 2 in Q1 2023.
  • Omega Fund Management's portfolio value fell 48% quarter-over-quarter to $153M.

Based on Omega Fund Management's 13F filing for Q1 2023, filed 15 May 2023.